Proficiency Testing Results for Heparin-Induced Thrombocytopenia in North America

Kristi J. Smock; Marlies R. Ledford-Kraemer; Piet Meijer; Peihong Hsu; Elizabeth M. Van Cott

doi:10.1055/s-0034-1365842

Seminars in Thrombosis and Hemostasis, Inhaltsverzeichnis

Semin Thromb Hemost 2014; 40(02): 254-260
DOI: 10.1055/s-0034-1365842

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Proficiency Testing Results for Heparin-Induced Thrombocytopenia in North America

Kristi J. Smock

¹Department of Pathology and ARUP Laboratories Institute for Clinical and Experiment Pathology, ARUP Laboratories, University of Utah, Salt Lake City, Utah

,

Marlies R. Ledford-Kraemer

²CLOT-ED, Inc., Islamorada, Florida

,

Piet Meijer

³ECAT Foundation, Leiden, The Netherlands

,

Peihong Hsu

⁴Department of Pathology/Laboratory Medicine, Hofstra North Shore-LIJ School of Medicine, Lake Success, New York

,

Elizabeth M. Van Cott

⁵Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts

› Institutsangaben

Abstract

Between 2010 and 2012, North American Specialized Coagulation Laboratory Association (NASCOLA) distributed five proficiency testing challenges to evaluate laboratory testing for heparin-induced thrombocytopenia (HIT). Results (n = 355) were submitted from 43 unique laboratories for 10 samples (3 positive, 2 weak positive, and 5 negative). The vast majority of results were from commercial enzyme-linked immunosorbent assay (ELISA) methods, predominantly polyvalent assays. Laboratories performed well in the classification of clear negative and positive samples. All results (100%) submitted for the five negative samples (n = 173) and 97% of immunological results submitted for the three positive samples (n = 105) were correctly classified (the incorrect responses were two borderline classifications and, from a gel-agglutination method, one negative classification). There was more difficulty in the classification of the two weak positive samples (n = 70). In one survey, 61% of results from the weak positive sample were classified as positive, while 21% were called negative, 16% were called borderline, and 2% were called inconclusive. In a second survey, 16% of results from the weak positive sample were called positive, while 56% were called negative, and 28% were called borderline. Significant interlaboratory variation was observed for ELISA results, with coefficients of variation of about 20 to 30%. We conclude that there is variability in HIT laboratory testing and that identification of weak positive samples can be challenging.

Keywords

heparin-induced thrombocytopenia - proficiency testing - ELISA - NASCOLA - ECAT

Volltext

Referenzen

References
1 Greinacher A, Farner B, Kroll H, Kohlmann T, Warkentin TE, Eichler P. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost 2005; 94 (1) 132-135
2 Prechel M, Walenga JM. Heparin-induced thrombocytopenia: an update. Semin Thromb Hemost 2012; 38 (5) 483-496
3 Lee GM, Arepally GM. Diagnosis and management of heparin-induced thrombocytopenia. Hematol Oncol Clin North Am 2013; 27 (3) 541-563
4 Stribling WK, Slaughter TF, Houle TT, Sane DC. Beyond the platelet count: heparin antibodies as independent risk predictors. Am Heart J 2007; 153 (6) 900-906
5 Tardy B, Presles E, Akrour M, de Maistre E, Lecompte T, Tardy-Poncet B. Experts' opinion or the serotonin release assay as a gold standard for the diagnosis of heparin-induced thrombocytopenia (HIT)?. J Thromb Haemost 2011; 9 (8) 1667-1669
6 Cuker A, Arepally G, Crowther MA , et al. The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion. J Thromb Haemost 2010; 8 (12) 2642-2650
7 Raschke RA, Curry SC, Warkentin TE, Gerkin RD. Improving clinical interpretation of the anti-platelet factor 4/heparin ELISA for the diagnosis of heparin-induced thrombocytopenia through the use of receiver operating characteristic analysis, stratum specific likelihood ratios, and Bayes theorum. Chest 2013; 144 (4) 1269-1275
8 Cuker A, Gimotty PA, Crowther MA, Warkentin TE. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood 2012; 120 (20) 4160-4167
9 Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994; 93 (1) 81-88
10 Zwicker JI, Uhl L, Huang WY, Shaz BH, Bauer KA. Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost 2004; 2 (12) 2133-2137
11 Baroletti S, Hurwitz S, Conti NA, Fanikos J, Piazza G, Goldhaber SZ. Thrombosis in suspected heparin-induced thrombocytopenia occurs more often with high antibody levels. Am J Med 2012; 125 (1) 44-49
12 Altuntas F, Matevosyan K, Burner J, Shen YM, Sarode R. Higher optical density of an antigen assay predicts thrombosis in patients with heparin-induced thrombocytopenia. Eur J Haematol 2008; 80 (5) 429-435
13 Warkentin TE, Sheppard JI, Moore JC, Sigouin CS, Kelton JG. Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost 2008; 6 (8) 1304-1312
14 Greinacher A, Ittermann T, Bagemühl J , et al. Heparin-induced thrombocytopenia: towards standardization of platelet factor 4/heparin antigen tests. J Thromb Haemost 2010; 8 (9) 2025-2031
15 Andrews DM, Cubillos GF, Paulino SK, Seckinger DL, Kett DH. Prospective observational evaluation of the particle immunofiltration anti-platelet factor 4 rapid assay in MICU patients with thrombocytopenia. Crit Care 2013; 17 (4) R143
16 Cuker A. Clinical and laboratory diagnosis of heparin-induced thrombocytopenia: An integrated approach. Semin Thromb Hemost 2014; 40 (1) 106-114
17 Cuker A, Rux AH, Hinds JL , et al. Novel diagnostic assays for heparin-induced thrombocytopenia. Blood 2013; 121 (18) 3727-3732
18 Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986; 67 (1) 27-30
19 Juhl D, Eichler P, Lubenow N, Strobel U, Wessel A, Greinacher A. Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia. Eur J Haematol 2006; 76 (5) 420-426
20 Amiral J, Wolf M, Fischer A, Boyer-Neumann C, Vissac A, Meyer D. Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia. Br J Haematol 1996; 92 (4) 954-959
21 Sylvester KW, Fanikos J, Anger KE , et al. Impact of an immunoglobulin G-specific enzyme-linked immunosorbent assay on the management of heparin-induced thrombocytopenia (epub ahead of print). Pharmacotherapy doi: 10.1002/phar.1322
22 Warkentin TE, Sheppard JA, Moore JC, Moore KM, Sigouin CS, Kelton JG. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need?. J Lab Clin Med 2005; 146 (6) 341-346
23 Lo GK, Sigouin CS, Warkentin TE. What is the potential for overdiagnosis of heparin-induced thrombocytopenia?. Am J Hematol 2007; 82 (12) 1037-1043
24 Price EA, Hayward CP, Moffat KA, Moore JC, Warkentin TE, Zehnder JL. Laboratory testing for heparin-induced thrombocytopenia is inconsistent in North America: a survey of North American specialized coagulation laboratories. Thromb Haemost 2007; 98 (6) 1357-1361
25 Tan CW, Ward CM, Morel-Kopp MC. Evaluating heparin-induced thrombocytopenia: the old and the new. Semin Thromb Hemost 2012; 38 (2) 135-143